OcuTerra Therapeutics
Peter Kaiser, MD, is the Founding Director of the Digital Optical Coherence Tomography Reading Center at the Cleveland Clinic’s Cole Eye Institute. He is actively involved in retinal clinical research as the study chairman of 4 major, multi-center, international clinical trials; as well as the principal investigator in multiple other trials. Peter is a major contributor to medical literature having authored several ophthalmology texts, and more than 200 book chapters, original reports, electronic publications and abstracts. He is also an associate editor at the American Journal of Ophthalmology, and serves on the editorial boards of Retina, Retina Today, Retinal Physician and Ocular Surgery News.
This person is not in the org chart
This person is not in any offices
OcuTerra Therapeutics
OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity